ArticleCancer science2025
PRRX2 Regulates GLI2 to Promote Proliferation, Invasion, and Metastasis by Inhibiting Senescence via Hedgehog Signaling.
Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Paired-related homeobox transcription factor 2 (PRRX2) belongs to the subfamily of homeobox genes and has been implicated as an oncogene in numerous cancer types, yet its role in pancreatic cancer requires further investigation. The aim of this study was to investigate the involvement of PRRX2 in pancreatic cancer progression. Bioinformatics analysis revealed that PRRX2, a transcription factor associated with senescence, was significantly upregulated in pancreatic cancer, and its heightened expression correlated with poor prognosis. Knockdown of PRRX2 led to an increased proportion of senescent cells and diminished proliferative, invasive, and metastatic capabilities, whereas PRRX2 overexpression yielded opposite effects. Subsequent experiments demonstrated that PRRX2 directly enhanced the transcription of GLI2, subsequently activating the hedgehog pathway, thereby inhibiting tumor senescence and promoting cell proliferation, invasion, and metastasis. Hedgehog pathway inhibitors or silencing of GLI2 partially reversed these effects. Additional replication experiments revealed that senescence inducers could partially counteract the impact of PRRX2 on pancreatic cancer. In conclusion, PRRX2 may serve as a potential therapeutic target for pancreatic cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.